期刊文献+

翁沥通胶囊对改善前列腺炎症状的疗效观察 被引量:2

Observation of therapeutic effect of wenglitong capsules for prostatitis symptoms
下载PDF
导出
摘要 目的:观察翁沥通胶囊在改善与前列腺炎相关临床症状的疗效。方法:对83例前列腺炎患者服用翁沥通胶囊12周,并辅以相关治疗;在服药后4、12周分别观察与前列腺炎相关临床症状和前列腺按摩液镜检情况。结果:在治疗后12周按摩前列腺液,白细胞消失26/83例(31.33%),白细胞<5个/HP32/83例(38.55%),白细胞<10个/HP23/83例(27.71%),白细胞>10个/HP2/83例(2.41%)。与前列腺炎相关的症状好转20/83例(24.1%),与前列腺炎相关的症状明显改善29/83例(34.94%),与前列腺炎相关的症状消失34/83例(40.96%)。结论:翁沥通胶囊在改善和治疗慢性前列腺炎方面有明显疗效,值得关注。 Objective:To evaluate the therapeutic effect of Wenglitong Capsule in improving the prostatitis related clinical symptoms. Methods: This study included 83 prostatitis patients who were treated with Wenglitong Capsule for 12 weeks, combining with related treatments. At the 4th and 12th weeks of treatment, the prostatitis related symptoms were evaluated and the PM liquid was examined under microscope. Results: At 12th week of treatment, WBC count decreased to normal in 26 of 83 patients (31.33%): WBC〈5/HP in 32(38.55%); WBC 〈10/ HP in 47(56.63%). Prostatitis related symptoms improved in 20 cases(24. 1%).significantly improved in 29 cases(34. 94%), and completely disappeared in34 cases(40. 96%). Conclusions: Wenglitong capsules present obvious improvement and cure therapeutic effect on Chronic prostatitis.
出处 《临床泌尿外科杂志》 2006年第11期857-858,共2页 Journal of Clinical Urology
关键词 前列腺炎 药物治疗 翁沥通胶囊 Prostatitis Treatemnt Wenglitong capsule
  • 相关文献

参考文献3

  • 1吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2004.589-591. 被引量:1430
  • 2朱忠宁,卢海刚,马士平,任雷鸣,苏骁,任新彩.翁沥通胶囊的药理作用研究[J].中国男科学杂志,2004,18(4):43-45. 被引量:17
  • 3Yavascaoglu I,Oktay B,Simsek U,et al. Role of ejaculation in the treatment of chronic non-bacterial prostatitis[J] .Int J Urol,1999,6:130-134. 被引量:1

二级参考文献4

共引文献1444

同被引文献9

  • 1王勤,冯高平,陈小琴.HPLC法测定普乐安片中芦丁的含量[J].西北药学杂志,2006,21(1):5-6. 被引量:4
  • 2宋丽晶,弥宏.妇科千金片实验研究和临床应用[J].中国乡村医药,2006,13(8):47-47. 被引量:22
  • 3Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999; 162(2): 369-375. 被引量:1
  • 4Litwin MS.A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Urology 2002; 60(6 Suppl): 14-18 discnssion: 18-19. 被引量:1
  • 5Schaeffer AJ, Knauss JS, Landis JR, et al. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 2002; 168(3): 1048-1053. 被引量:1
  • 6Chung M, Vashi V, Puente J, et al. Clinical phannacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system(GITS) formulation. Br J Pharmacol 1999; 48(5): 678-687. 被引量:1
  • 7Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003; 91(1): 41-44. 被引量:1
  • 8Yavascaoglu I, Oktay B, Simsek U, et al. Role of ejaculation in the treatment of chronic non-bacterial prostatitis. Int J Urol 1999; 6(3): 130-134. 被引量:1
  • 9Litwin MS,Mc Naughton-Collins M,Fowler FJ Jr,et al.The National Institutes of Health chronic prostatitis symptom index:development and validation of a new outcome measure,Chronic Prostatitis Collaborative Research Network[J].J Urol,1999,162(2):369-375. 被引量:1

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部